Study of VYNT-0126 in the Treatment of Rett Syndrome in Adult Patients
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This is an exploratory, Phase 2, multicenter, double-blind, parallel-group,
placebo-controlled study to assess the safety, tolerability, and efficacy of oral treatment
with VYNT-0126 in female subjects 18-45 years of age with Rett syndrome.